Clinical Scorecard: Analysis of Global Research Trends in Immunoconjugates for Cervical Cancer: A Bibliometric and Thematic Mapping Study from 2015 to 2024

At a Glance

Key Highlights

• Tisotumab vedotin is the first FDA-approved antibody-drug conjugate for recurrent/metastatic cervical cancer, targeting tissue factor with demonstrated efficacy and manageable toxicity.
• Emerging immunoconjugates such as sacituzumab govitecan and trastuzumab deruxtecan show promising objective response rates in pretreated and HER2-expressing cervical cancers.
• Research trends have shifted from preclinical mechanistic studies to clinical translation focusing on safety optimization, combination therapies, and biomarker-guided approaches.

Guideline-Based Recommendations

Diagnosis

• Confirm antigen expression (e.g., tissue factor, Trop-2, HER2) to identify candidates for antibody-drug conjugate therapy.

Management

• Use antibody-drug conjugates like tisotumab vedotin after progression on chemotherapy in recurrent/metastatic cervical cancer.
• Consider combination regimens with carboplatin, bevacizumab, or immune checkpoint inhibitors based on ongoing clinical trials.
• Implement ocular toxicity mitigation strategies and monitor for peripheral neuropathy during treatment.

Monitoring & Follow-up

• Vigilant monitoring for ocular adverse events due to boxed warnings associated with tisotumab vedotin.
• Regular assessment for peripheral neuropathy and hematologic toxicities such as neutropenia.

Risks

• Ocular toxicity requiring preventive measures and patient education.
• Peripheral neuropathy necessitating dose adjustments or treatment interruptions.
• Potential resistance mechanisms and tumor heterogeneity impacting treatment efficacy.

Patient & Prescribing Data

Patients with recurrent or metastatic cervical cancer post-chemotherapy progression

Tisotumab vedotin shows a 24% objective response rate with median progression-free survival of 4.2 months and overall survival of 12.1 months; combination therapies under investigation may improve response rates up to 55%.

Clinical Best Practices

• Select patients based on antigen expression profiling to optimize antibody-drug conjugate efficacy.
• Incorporate multidisciplinary care teams to manage and monitor treatment-related toxicities.
• Utilize biomarker-guided approaches and consider combination strategies with immune checkpoint inhibitors to overcome resistance.
• Educate patients on potential ocular risks and implement preventive ocular care protocols.
• Engage patients in clinical trials to access emerging immunoconjugate therapies and contribute to evolving evidence.

References

• FDA Approval of Tisotumab Vedotin
• InnovaTV 204 Trial Results
• Sacituzumab Govitecan Phase II Trial
• DESTINY-PanTumor02 Study
• Global Cancer Statistics 2022